Wisconsin
Prescription drug spending and prescribing in Wisconsin, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $4.9B for prescriptions written in Wisconsin, the 21st most of 52 states and territories, and 3.3% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $4.9B
- Medicaid drugs, 2025: $2.1B
- Opioid share of claims: 3.3%
- Life-science raises, 2 years: $100M
Opioid share of Part D claims, 2024
Wisconsin outlined; every state in quartiles. Click a state to compare.
- Up to 3.2%
- 3.2% to 3.7%
- 3.7% to 4.3%
- Over 4.3%
| Share of Part D claims | Wisconsin | United States | Difference |
|---|---|---|---|
| Opioids | 3.3% | 3.5% | −8% |
| Antibiotics | 3.8% | 4.4% | −13% |
| Antipsychotics | 2.0% | 1.7% | +17% |
| Drug | Against national rate | Claims |
|---|---|---|
| Lisdexamfetamine dimesylate | 3.0× | 22,588 |
| Sodium chloride/nahco3/kcl/peg | 2.7× | 18,533 |
| Insulin glargine-yfgn | 2.4× | 26,121 |
| Warfarin sodium | 2.4× | 220,299 |
| Pen needle,dual safety,diabetc | 2.3× | 16,183 |
| Trihexyphenidyl HCl | 2.0× | 7,733 |
| Dofetilide | 1.9× | 12,054 |
| Fluticasone furoate | 1.9× | 23,309 |
| Methylphenidate HCl | 1.9× | 31,437 |
| Doxycycline monohydrate | 1.8× | 66,529 |
- Centaur Health Holdings, Inc.$50M · Other health care · Apr 21, 2026
- ENSODATA, INC.$20M · Other health care · Jun 27, 2025
- Centaur Health Holdings, Inc.$6.0M · Other health care · Jul 14, 2025
- NOVIR, INC.$3.1M · Other health care · Aug 20, 2026
- GenoPalate, Inc.$3.0M · Biotech · Dec 10, 2024
- WISC MED, LLC$3.0M · Other health care · Aug 15, 2025
- Protegera, Inc.$3.0M · Other health care · Jan 27, 2025
- Protegera, Inc.$2.5M · Other health care · Mar 5, 2026
- Lumoptik, Inc.$1.5M · Other health care · Sep 18, 2026
- aMBR Genomics, Inc.$1.1M · Other health care · Mar 31, 2026
- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- Alabama et al. v. Endo International, No. 3:19-cv-04157 (N.D. Cal. July 19, 2019)2019 · Settled
- California et al. v. Teikoku Seikayu Co.(Lidoderm), No. 3:18-cv-00675 (N.D. Cal. 01/31/18)2018 · Settled
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
- Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)2004 · Settled
- In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)2003 · Settled
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG